You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Express Scripts
AstraZeneca
Medtronic
Merck

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,994,575

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,994,575 protect, and when does it expire?

Patent 9,994,575 protects AYVAKIT and is included in one NDA.

This patent has thirty-four patent family members in twenty-seven countries.

Summary for Patent: 9,994,575
Title:Compositions useful for treating disorders related to kit
Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
Inventor(s): Hodous; Brian L. (Cambridge, MA), Kim; Joseph L. (Wayland, MA), Wilson; Kevin J. (Boston, MA), Wilson; Douglas (Ayer, MA), Zhang; Yulian (Acton, MA)
Assignee: BLUEPRINT MEDICINES CORPORATION (Cambridge, MA)
Application Number:14/887,614
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Recent additions to Drugs Protected by US Patent 9,994,575

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Blueprint Medicines AYVAKIT avapritinib TABLET 212608 Jan 9, 2020 RX Yes   Start Trial Y Y   Start Trial U-2726 TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 9,994,575

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-001 Jan 9, 2020 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION   Start Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-002 Jan 9, 2020 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION   Start Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-003 Jan 9, 2020 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,994,575

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 098054   Start Trial
Australia 2014337314   Start Trial
Brazil 112016008541   Start Trial
Canada 2926999   Start Trial
China 105658652   Start Trial
China 110003217   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Moodys
Boehringer Ingelheim
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.